Clinical trials evaluating the pill included adults without diabetes who had a body‑mass index (BMI) of at least 30, or at least 27 with an obesity‑related health condition, reflecting typical eligibility criteria for chronic weight‑management therapies.

How the Pill Works Compared With Injectable Wegovy

The pill and the injectable form of Wegovy share the same active ingredient: semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist. These medicines mimic a hormone that helps regulate appetite, slows stomach emptying, and increases feelings of fullness, leading to reduced calorie intake.

The main difference is how the drug is delivered:

• Oral Wegovy: taken once daily as a 25 mg tablet.
• Injectable Wegovy: administered as a once‑weekly subcutaneous injection.

By removing the need for injections, the pill could make GLP‑1 therapy more accessible to people who prefer oral medications or are hesitant to use injectable treatments.

Key Results From the OASIS 4 Clinical Trial

Evidence supporting the pill’s effectiveness comes from the Phase 3 OASIS 4 trial, which tested once‑daily oral semaglutide in adults with obesity or overweight and at least one related health condition.

Key findings from the 64‑week study:

• Participants receiving oral semaglutide 25 mg lost an average of about 16.6% of their body weight when adherence to treatment was considered.
• Participants taking placebo lost about 2.7% of body weight over the same period.
• More than one‑third of treated participants lost at least 20% of their body weight, far higher than in the placebo group.

Researchers also reported that the weight‑loss results were comparable to outcomes seen with injectable semaglutide therapies, suggesting the oral formulation can deliver similar clinical benefits.

FDA Approval and U.S. Launch

Before the EMA recommendation, the therapy already reached the U.S. market.

• The U.S. Food and Drug Administration approved the once‑daily Wegovy pill on December 22, 2025, making it the first oral GLP‑1 receptor agonist authorized specifically for weight management.
• Novo Nordisk launched the drug in the United States on January 5, 2026.

At launch, introductory self‑pay prices started around $149 per month for lower‑dose starter versions, with higher maintenance doses priced higher.

Why the EMA Recommendation Is Significant

The EMA committee’s recommendation is important for several reasons.

1. First oral obesity drug in Europe
If approved, the therapy would likely become the first oral GLP‑1 treatment for weight loss in the EU, opening a new treatment format in a market previously dominated by injectable drugs.

2. Potentially broader patient adoption
Daily pills are generally easier for many patients to use than injections, which could increase acceptance and adherence to treatment.

3. Expansion of the obesity drug market
Europe’s obesity‑drug market has grown rapidly with GLP‑1 injections such as Wegovy. Adding a pill option could further expand demand by lowering barriers to starting treatment.

4. Intensifying industry competition
The development also heightens competition among pharmaceutical companies developing oral obesity medicines, particularly as rivals pursue their own GLP‑1–based pills and next‑generation metabolic drugs.

The Bigger Picture for Obesity Treatment

Obesity is increasingly treated as a chronic metabolic disease, and GLP‑1 drugs have reshaped the field by delivering double‑digit percentage weight loss in many patients. The arrival of an effective pill formulation could represent the next phase of that shift.

If the European Commission follows the EMA’s recommendation, the Wegovy pill would move the market beyond injection‑only GLP‑1 therapies and could significantly broaden access to pharmacological weight‑management treatment across Europe.

Clinical trials evaluating the pill included adults without diabetes who had a body‑mass index (BMI) of at least 30, or at least 27 with an obesity‑related health condition, reflecting typical eligibility criteria for chronic weight‑management therapies.

How the Pill Works Compared With Injectable Wegovy

The pill and the injectable form of Wegovy share the same active ingredient: semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist. These medicines mimic a hormone that helps regulate appetite, slows stomach emptying, and increases feelings of fullness, leading to reduced calorie intake.

The main difference is how the drug is delivered:

• Oral Wegovy: taken once daily as a 25 mg tablet.
• Injectable Wegovy: administered as a once‑weekly subcutaneous injection.

By removing the need for injections, the pill could make GLP‑1 therapy more accessible to people who prefer oral medications or are hesitant to use injectable treatments.

Key Results From the OASIS 4 Clinical Trial

Evidence supporting the pill’s effectiveness comes from the Phase 3 OASIS 4 trial, which tested once‑daily oral semaglutide in adults with obesity or overweight and at least one related health condition.

Key findings from the 64‑week study:

• Participants receiving oral semaglutide 25 mg lost an average of about 16.6% of their body weight when adherence to treatment was considered.
• Participants taking placebo lost about 2.7% of body weight over the same period.
• More than one‑third of treated participants lost at least 20% of their body weight, far higher than in the placebo group.

Researchers also reported that the weight‑loss results were comparable to outcomes seen with injectable semaglutide therapies, suggesting the oral formulation can deliver similar clinical benefits.

FDA Approval and U.S. Launch

Before the EMA recommendation, the therapy already reached the U.S. market.

• The U.S. Food and Drug Administration approved the once‑daily Wegovy pill on December 22, 2025, making it the first oral GLP‑1 receptor agonist authorized specifically for weight management.
• Novo Nordisk launched the drug in the United States on January 5, 2026.

At launch, introductory self‑pay prices started around $149 per month for lower‑dose starter versions, with higher maintenance doses priced higher.

Why the EMA Recommendation Is Significant

The EMA committee’s recommendation is important for several reasons.

1. First oral obesity drug in Europe
If approved, the therapy would likely become the first oral GLP‑1 treatment for weight loss in the EU, opening a new treatment format in a market previously dominated by injectable drugs.

2. Potentially broader patient adoption
Daily pills are generally easier for many patients to use than injections, which could increase acceptance and adherence to treatment.

3. Expansion of the obesity drug market
Europe’s obesity‑drug market has grown rapidly with GLP‑1 injections such as Wegovy. Adding a pill option could further expand demand by lowering barriers to starting treatment.

4. Intensifying industry competition
The development also heightens competition among pharmaceutical companies developing oral obesity medicines, particularly as rivals pursue their own GLP‑1–based pills and next‑generation metabolic drugs.

The Bigger Picture for Obesity Treatment

Obesity is increasingly treated as a chronic metabolic disease, and GLP‑1 drugs have reshaped the field by delivering double‑digit percentage weight loss in many patients. The arrival of an effective pill formulation could represent the next phase of that shift.

If the European Commission follows the EMA’s recommendation, the Wegovy pill would move the market beyond injection‑only GLP‑1 therapies and could significantly broaden access to pharmacological weight‑management treatment across Europe.